Collaborations

Drug company enters agreement to bring hepatitis B vaccine to European market

Published in Hepatitis Weekly, March 14th, 2005

The directors of SciGen Limited, a biopharmaceutical company announced that the company has entered into an agreement with European biotechnology company Berna Biotech AG to be SciGen's exclusive distributor for Sci-B-Vac in Western Europe.

SciGen's entry into the European market has been made possible as a consequence of SciGen acquiring worldwide rights to Sci-B-Vac, its third generation hepatitis B vaccine.

The Commercialization Agreement between SciGen and Berna comprehends annual minimum orders by Berna over an initial 5-year term generating significant revenues for the company. The agreement provides for automatic renewals, with a 1-year notice...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry